Corrigendum to 'Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival': [Annals of Oncology Volume 32, Issue 8, August 2021, Pages 1015-1024].

Slamon, D JNeven, PChia, SJerusalem, GDe Laurentiis, MIm, SPetrakova, KValeria Bianchi, GMartín, MNusch, ASonke, G SDe la Cruz-Merino, LBeck, J TJi, YWang, CDeore, UChakravartty, AZarate, J PTaran, TFasching, P A2025-01-072025-01-072021-08-16https://hdl.handle.net/10668/27558enAttribution-NonCommercial-NoDerivatives 4.0 Internationalhttp://creativecommons.org/licenses/by-nc-nd/4.0/Corrigendum to 'Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival': [Annals of Oncology Volume 32, Issue 8, August 2021, Pages 1015-1024].research article34412950open access10.1016/j.annonc.2021.07.0111569-8041http://www.annalsofoncology.org/article/S0923753421022092/pdf